Table 2.
Summary of Neisseria gonorrhoeae Recovery Rate at Baseline in the Microbiologically Evaluable Population
| Specimen Source | Gepotidacin 1500 mg (n = 30) |
Gepotidacin 3000 mg (n = 39) |
Total (N = 69) | |||
|---|---|---|---|---|---|---|
| Number | Recovery Rate (%) | Number | Recovery Rate (%) | Number | Recovery Rate (%) | |
| Urogenital | ||||||
| Overall | 30 | 100 | 39 | 100 | 69 | 100 |
| Male | 29 | 97 | 38 | 97 | 67 | 97 |
| Female | 1 | 3 | 1 | 3 | 2 | 3 |
| Pharyngeal | ||||||
| Overall | 0 | ... | 2 | 5 | 2 | 3 |
| Male | 0 | ... | 2 | 5 | 2 | 3 |
| Female | 0 | ... | 0 | ... | 0 | ... |
| Rectal | ||||||
| Overall | 1 | 3 | 2 | 5 | 3 | 4 |
| Male | 1 | 3 | 2 | 5 | 3 | 4 |
| Female | 0 | ... | 0 | ... | 0 | … |
The numbers of participants in the treatment groups and total were used as denominators.